

鄭鈞文教授 研究室簡介

學歷：

國立台灣大學生化科技所(原農業化學所)生化營養組博士 (1990-1994)

國立台灣大學農業化學所應用微生物組碩士 (1988-1990)

國立台灣大學農業化學系學士 (1984-1988)

現職暨學會會員：

中山醫學大學醫學院醫學研究所教授

美國癌症醫學研究學會(AACR)會員

歐洲癌症醫學研究學會(EACR)會員

癌症轉移研究學會會員(MRS)會員

經歷：

國科會專題研究計畫初審委員(104-108年)

國科會專題研究計畫複審委員(103年)

國科會專題研究計畫初審委員(101、102年)

國科會大專生專題研究計畫初審委員(102年)

中山醫學大學醫學研究所教授 (2020/08-迄今)

中山醫學大學生化微生物免疫研究所教授 (2016/08 - 2020/07)

中山醫學大學生化暨生物科技研究所教授 (2013/02 - 2016/07)

中山醫學大學醫學院生化暨生物科技研究所副教授 (2007/12-2013/01)

中山醫學大學醫學院生化暨生物科技研究所助理教授 (2003/07-2007/11)

中國醫藥大學附設醫院醫學研究部顧問 (2013)

國防大學國防醫學院公共衛生研究所兼任助理教授 (2000-2004)

元培科學技術學院醫事技術系助理教授 (2001/08-2003/07)

元智大學通識教育中心兼任助理教授 (2001-2003)

中央研究院生物醫學科學研究所博士後研究員 (1999-2001)

台灣大學醫學院藥物發展研究群博士後研究員 (1997-1999)

中央研究院植物學研究所博士後研究員 (1996-1997)

44期少尉義務役軍官 (1994-1996)

研究室地點：研究大樓五樓 509 研究室

連絡方式: 04-24730022 分機 11677

E-mail：cwcheng@csmu.edu.tw

一、實驗室研究方向

Principle investigator: Professor Chun-Wen Cheng

Breast cancer (BC) cases have been rising at an alarming rate in the past two decades in Taiwan. Similar to global trends, majority of these BC cases are of ER+ nature (ER+BC). However, unlike the trend in western countries, in Taiwan the primary contributor to this phenomenon have been young (premenopausal) women. With our great interest in molecular oncology studies regarding genetic interactions and oncogenic and tumor suppressor networks that dictate cancer progression, metastasis and stem cell regulation. We also shared a broad research in providing experience with the mouse genetics in cancer development, molecular and cell biology techniques in clarifying tumor cell metastasis and drug development in cancer pharmacology and endocrinology pharmacology.

Based on our previous investigations for breast cancer in Taiwan, our goals directed toward the risk susceptibility genes modified by estrogen exposure in contributing for cell tumorigenesis in female breast cancer. We attempted to promote the issue regarding from cell oncogenesis to cancer cell worsen and mechanisms associated with breast carcinogenesis. On the basis of previous studies in breast cancer, our data supported the evidences that breast cancer can be initiated by estrogen exposure, DNA damage caused by catechol-estrogen metabolizing and DNA repair systems on cancer risk in Taiwanese might yield valuable clues on the association of breast tumorigenesis (Cancer Research (1999) 59:4870-4875; Oncogene (2001) 20:3814-3823; Int J Cancer (2005) 113:345-53; Breast Cancer Res Treat (2008) 111:145-55; Carcinogenesis (2009) 30:1562-70; Clin Chim Acta (2010) 411:234-241; Ann Surg Oncol (2010) 17:760-71; Clin Cancer Res (2010) 16:3473-84. Breast Cancer Res (2011) 13(1):R13).

Recently, we paid attention to examining the molecular marker for the early prediction of disseminated tumor cells having micrometastasis in lymph node tissues. Our lab collaborated with Dr. Chen-Yang Shen at IBMS, Academia Sinica, and they identified several tumor suppressive microRNAs (miRNAs) decreased breast cancer metastasis via down-modulating the EMT-related genes (Breast Cancer Res Treat (2012) 134:1081-93; Hum Mol Genet (2013) 23:355-67; J Pathol (2015) 237:25-37; Oncotarget (2015) 6:44222-38; Oncotarget (2016) 7:16462-16478; Cell Physiol Biochem (2018) 48:2205-2218). In summary, based on broad scientific interests includes basic laboratory research in DNA damage/repair, molecular and genetic epidemiology, genomic prediction models of survival, precision medicine, and cancer health disparities, which are of benefit in providing important clues in contributing the molecular mechanisms involved in cell oncogenesis, tumor progression and thus more comprehensively understanding the etiological role of cell facilitate advances in prognostic evaluation of female breast cancer in Taiwan. During the achievement in scientific research in breast cancer, the awards mentioned in the followings:

1999	Young Investigator Research Award, American Association for Cancer Research 美國癌症醫學會年輕學術研究獎
2013-2016	MERIT award, National Science Council, Taiwan 國科會傑出學者養成計畫
2002	Breast Cancer Research Award, 2018 Taiwan Joint Cancer Conference Taiwan Association of Gynecologic Oncologists 第七屆台灣癌症聯合學術年會優秀論文獎 台灣婦癌醫學會

近年來，研究報告指出 miRNA 異常表現與腫瘤生成、癌發展進程和預後有密切

關聯。因此，找尋新的 miRNA 生物標記(biomarker)做為評估乳癌預後，甚至是提供臨床治療藥物抗性的研發資訊則更形重要。鑒於我們實驗室以往對 EMT 連結基因表現調控的研究，探討 miRNAs 表觀基因調節機制和癌症預後關聯。我們透過 miRNA 晶片分析結合生物資訊軟體，在不同癌病灶細胞株(in vitro)和小鼠腫瘤異體移植 (in vivo)建立 miRNA 的研究模式，在近五年的所發表的文章有17 篇，其中有7篇為通訊作者。以分子選殖技術建構穩定且持續表達腫瘤抑制性 miRNA (tumor suppressive miRNAs；miR-30a, miR-622, miR-9, miR-221和 miR-34)的乳癌細胞株，驗證 miRNA 和部分致癌基因(oncogenes)的作用機轉，確認 miR-30a/Slug、miR-30a/vimentin、FOXO3a/miR-622/ HIF-1 α 和 miR-139/CXCR4-pAkt 的轉譯抑制作用。藉由 miRNA 基因關閉(knock-down)和基因重開啟(knock-in)的實驗設計，以 wound-healing assay、Boyden chamber invasion/migration assay 佐以 Western blotting 蛋白定量和共軛對焦螢光顯微技術(confocal fluorescence microscope)，確認 miRNA 在抑癌侵襲轉移癌所扮演的角色。此外，miRNA 參與乳癌幹細胞的生成，關係到癌細胞自我更新、再分化和藥物抗性和惡性進程發展的特性。特別是我們發現 miRNA 彼此間具有協同交互作用，藉由網路生物資訊軟體 ALLGEN PROMO 預測染色體操作子上游轉錄起始點的單核苷酸多型性變異(single nucleotide polymorphisms, SNPs)攸關 miRNA 的轉錄表現，會影響乳癌進程及預後。免疫療法標的 PD-L1抑制劑 atezolizumab 合併化療藥物 nab-paclitaxel 的臨床研究試驗結果證實可作為三陰性乳癌第一線治療；但是，文獻上探討 miRNA 調控 PD-L1表現，進而關係到乳癌幹細胞生成、不同分子亞型的抗藥性反應及其預後評估仍有許多議題尚待釐清。有趣的是，不同於西方國家，亞洲地區乳癌的高發生危險群又多以年輕(停經前)婦女為主，況且在先前的乳癌研究中，我們發現雌激素受體陽性(estrogen receptor-positive (ER+))在台灣年輕女性乳癌具有獨特的臨床和病理特徵。這些特徵的關鍵在於血清中有高濃度的雌二醇 (E2)，意味著 E2 在族群/地理等特性與 ER+ 年輕女性乳癌發生有關。因此，我們設計以單細胞 Exome-Seq/RNA-seq 找出關於 ER+ 乳癌癌生的候選標的 miRNA 或是 lncRNA 分子，探討新穎候選基因因雌激素活化界島免疫作用失調後，導向乳癌幹細胞(BCSCs)得以發展自我更新和分化等特性(pluripotency)，進而強化乳癌細胞侵襲轉移。

二、研發成果：

(一) 醫研所專任教師論文發表一覽表 (請填入件數的數字)

學 年 度	姓 名	職 稱	SCI						非 SCI 篇數	與國 外機 構合 作完 成的 篇數
			第 一 作 者 論 文 篇 數	非第 一作 者之 通訊 作者 論文 篇數	非第一 或通訊 作者之 其他序 位作者 論文篇 數	總篇 (件) 數 (以 上三 項總 和)	IF>5 (不限 作者 序)	領域 排名 前 20% (以第 一作 者或 通訊 作者 發表)		
108	鄭鈞文	教授	1	0	0	1	0	0	0	0

107	鄭鈞文	教授	1	0	0	1	1	1	0	0
106	鄭鈞文	教授	0	1	4	5	3	1	0	0
105	鄭鈞文	教授	0	0	0	0	0	0	0	0
104	鄭鈞文	教授	1	0	2	3	3	1	0	1
103	鄭鈞文	教授	0	0	0	0	0	0	0	0
102	鄭鈞文	教授	0	0	1	1	1	0	0	0
101	鄭鈞文	副教授	2	0	0	2	0	2	0	0
100	鄭鈞文	副教授	0	0	1	1	1	0	0	0
99	鄭鈞文	副教授	1	1	1	3	1	2	0	0
98	鄭鈞文	副教授	0	0	1	1	0	1	0	0
97	鄭鈞文	副教授	1	0	1	2	0	1	0	0
96	鄭鈞文	助理教授	0	2	0	2	0	2	0	0
總計			7	4	11	22	10	11	0	1

(二) 論文發表：(*, Corresponding author)

1. Huang YC, Chang YW, **Cheng CW**, Wu CM, Liao WL, Tsai FJ. Causal relationship between adiponectin and diabetic retinopathy: a Mendelian randomization study in an Asian Population. *Genes*. Accepted; 2020, Dec., Available online. (IF=3.759; Ranking=53/177, Genetics & Heredity)
2. **Cheng CW**, Sheu GT, Chou JS, Wang PH, Cheng YC, Lai CY. Fine particulate matter PM_{2.5} generated by building demolition increases the malignancy of breast cancer MDA-MB-231 cells. *Chemosphere*. 2020; Nov., Available online. (IF=5.778; Ranking=15/128, Environ Sci)
3. Hsieh YH, Syu RJ, Lee CC, Lin SH, Lee CH, **Cheng CW**, Tsai JP. Arecoline induces epithelial mesenchymal transition in HK2 cells by upregulating the ERK-mediated signaling pathway. *Environ Toxicol*. 2020; 35:1007-1014. (IF=3.118; Ranking=39/92, Toxicology)
4. Liao WL, Lin JY, Shieh JC, Yeh HF, Hsieh YH, Cheng YC, Lee HJ, Shen CY, **Cheng CW***. Induction of G2/M phase arrest by diosgenin via activation of Chk1 Kinase and Cdc25C regulatory pathways to promote apoptosis in human breast cancer cells. *Int. J Mol. Sci*. 2019; 21:172. (IF=4.556; Ranking=74/297, Biochem & Mol Biol)
5. **Cheng CW***, Yu JC, Hsieh YH, Liao WL, Shieh JC, Yao CC, Lee HJ, Chen PM, Wu PE, Shen. Increased Cellular Levels of MicroRNA-9 and MicroRNA-221 Correlate with Cancer Stemness and Predict Poor Outcome in Human Breast Cancer. *Cell Physiol Biochem*. 2018; 48:2205-2218. (IF=5.500; Ranking=8/83, Physiol)
6. Lin CL, Lee CH, Chen CM, **Cheng CW**, Chen PN, Ying TH, Hsieh YH. Protodioscin Induces Apoptosis Through ROS-Mediated Endoplasmic Reticulum Stress via the JNK/p38 Activation Pathways in Human Cervical Cancer Cells. *Cell Physiol Biochem* 2018; 46:322-334. (IF=5.500; Ranking=8/83, Physiol)
7. Lee YC, **Cheng CW**, Lee HJ, Chu HC. Apple Polyphenol Suppresses

Indomethacin-Induced Gastric Damage in Experimental Animals by Lowering Oxidative Stress Status and Modulating the MAPK Signaling Pathway. *J Med Food* 2017; 20:1113-1120. (IF=2.040; Ranking=48/130, Food Sci & Techol)

8. Lin CL, Chen CM, Lin CL, **Cheng CW**, Lee CH, Hsieh YH. Norcantharidin induces mitochondrial-dependent apoptosis through Mcl-1 inhibition in human prostate cancer cells. *Biochim Biophys Acta* 2017; 1864:1867-1876. (IF=4.521; Ranking=61/286, Biochem & Mol Biol)
9. Shyu HY, Chen MH, Hsieh YH, Shieh JC, Yen LR, Wang HW, **Cheng CW***. Association of eNOS and Cav-1 gene polymorphisms with susceptibility risk of large artery atherosclerotic stroke. *PLoS One* 2017; 12: e0174110. (IF=2.806; Ranking=15/64, Multidisciplinary Sci)
10. Chen CM, Lin CL, Chiou HL, Hsieh SC, Lin CL, **Cheng CW**, Hung CH, Tsai JP, Hsieh YH. Loss of endothelial cell-specific molecule 1 promotes the tumorigenicity and metastasis of prostate cancer cells through regulation of the TIMP-1/MMP-9 expression. *Oncotarget* 2017; 8:13886-1389. (IF=5.168; Ranking=44/217, Oncology)
11. Tung JN, Ko CP, Yang SF, **Cheng CW**, Chen PN, Chang CY, Lin CL, Yang TF, Hsieh YH, Chen KC. Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo. *J Neuro-Oncol* (IF=3.070; Ranking=59/192, Oncology)
12. Chang CW, Yu JC, Hsieh YH, Yao CC, CHao JI, Chen PM, Hsieh HY, Hsiung CN, Chu HW, Shen CY, **Cheng CW***. MicroRNA-30a increases tight junction protein expression to suppress the epithelial-mesenchymal transition and metastasis by targeting Slug in breast cancer. *Oncotarget* 2016; 7:16462-16478. (IF=5.168; Ranking=44/217, Oncology)
13. Lin MT, Lin CL, Lin TY, **Cheng CW**, Yang SF, Lin CL, Wu CC, Hsieh YH, Tsai JP. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway. *Tumor Biol* 2016; 37:6987-6996. (IF=3.611; Ranking=69/211, Oncology)
14. **Cheng CW***, Chen PM, Hsieh YH, Weng CC, Chang CW, Yao CC, Hu LY, Wu PE, Shen CY. Foxo3a-mediated overexpression of microRNA-622 suppresses tumor metastasis by repressing hypoxia-inducible factor-1 α in erk-responsive of lung cancer. *Oncotarget* 2015; 6:44222-44238. (IF=5.008; Ranking=36/213, Oncology)
15. Hsieh YH, Hsieh SC, Lee CH, Yang SF, **Cheng CW**, Tang MJ, Lin CL, Lin CL, Chou RH. Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway. *Oncotarget* 2015; 6:34859-34874. (IF=5.008; Ranking=36/213, Oncology)
16. Grelet S, Andries V, Polette M, Gilles C, Staes K, Martin AP, Kileztky C, Terryn C, Dalstein V, **Cheng CW**, Shen CY, Birembaut P, Van Roy F, Nawrocki-Raby B. The human NANOS3 gene contributes to lung tumour invasion by inducing epithelial-mesenchymal transition. *J Pathol* 2015; 237:25-37. (IF=7.429; Ranking=16/211, Oncology)

17. Tseng TL, Lai WC, Lee TL, Hsu WH, Sun YW, Li WC, **Cheng CW**, Shieh JC. A role of *Candida albicans* CDC4 in the negative regulation of biofilm formation. *Can J Microbiol* 2015; 61:247-55. (IF=1.221; Ranking=122/163, Biotechnology & Microbiology)
18. Chu HW, **Cheng CW**, Chou WC, Hu LY, Wang HW, Hsiung CN, Hsu HM, Wu PE, Hou MF, Shen CY, Yu JC. A Novel Estrogen Receptor-microRNA 190a-PAR-1-Pathway Regulates Breast Cancer Progression, A finding initially suggested by genome-wide analysis of loci associated with lymph-node metastasis. *Hum Mol Genet* 2014; 23:355-367. (IF=6.393; Ranking=32/290, Biochemistry & Molecular Biology)
19. Hsieh SC, Huang MH, **Cheng CW**, Hung JH, Yang SF, Hsieh YH. α -Mangostin induces mitochondrial dependent apoptosis in human hepatoma SK-Hep-1 cells through inhibition of p38 MAPK pathway. *Apoptosis* 2013; 18:1548-1560. (IF=3.949; Ranking=84/289, Biochemistry & Molecular Biology)
20. Tung MC, Hsieh SC, Yang SF, **Cheng CW**, Tsai RT, Wang SC, Huang MH, Hsieh YH. Knockdown of lipocalin-2 suppresses the growth and invasion of prostate cancer cells. *Prostate* 2013; 73:1281-1290. (IF=3.843; Ranking=9/73, Urology & Nephrology)
21. **Cheng CW***, Liu YF, Yu JC, Wang HW, Ding SL, Hsiung CN, Hsu HM, Wu PE, Shen CY. Prognostic significance of Cyclin D1, β -catenin, and MTA1 in patients with invasive ductal carcinoma of the breast. *Ann Surg Oncol* 2012; 19:4129-39. (IF=4.120; Ranking=9/199, Surgery)
22. **Cheng CW***, Wang HW, Chang CW, Chu HW, Chen CY, Yu JC, Chao JI, Liu HF, Ding SL, Shen CY. MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. *Breast Cancer Res Treat* 2012; 134:1081-1093. (IF=4.469; Ranking=43/197, Oncology)
23. Shyu HY, Shieh JC, Lin JH, Wang HW, **Cheng CW***. Polymorphisms of DNA repair pathway genes and cigarette smoking in relation to susceptibility of large artery atherosclerotic stroke among ethnic Chinese in Taiwan. *J Atheroscler Thromb* 2012; 19:316-325. (IF=2.933; Ranking=19/68, Peripheral vascular disease)
24. Ho YJ, Tai SY, Pawlak CR, Wang AL, **Cheng CW**, Hsieh MH. Behavioral and IL-2 responses to diosgenin in ovariectomized rats. *Chin J Physiol* 2012; 55:91-100. (IF=1.275; Ranking=65/81, Physiology)
25. Yu JC, Hsiung CN, Hsu HM, Bao BY, Chen ST, Hsu GC, Chou WC, Hu LY, Ding SL, **Cheng CW**, Wu PE, Shen CY. Genetic variation in the genome-wide predicted estrogen response element-related sequences is associated with breast cancer development and progression. *Breast Cancer Res* 2011; 13:R13. (IF=5.245; Ranking=28/196, Oncology)
26. Lai WC, Tseng TL, Jian T, Lee TL, **Cheng CW**, Shieh JC. Construction of *Candida albicans* Tet-on tagging vectors with an Ura-blaster cassette. *Yeast* 2011; 28:253-263. (IF=1.955; Ranking=12/23, Mycology)
27. Chang WT, Pan CY, Rajanbabu V, **Cheng CW**, Chen JY. Tilapia (*Oreochromis mossambicus*) antimicrobial peptide, hepcidin 1-5, shows antitumor activity in cancer cells. *Peptides* 2011; 32:342-352. (IF=2.434; Ranking=114/261, Pharmacology & Microbiology)

Pharmacy)

28. Fong CS, Shyu HY, Shieh JC, Fu YP, Chin TY, Wang HY, **Cheng CW***. Association of *MTHFR*, *MTR*, and *MTRR* polymorphisms with Parkinson's disease among ethnic Chinese in Taiwan. *Clin Chim Acta* 2011; 412:332-338. (IF=2.535; Ranking=6/32, Medical Laboratory Technology)
29. Maa MC, Chang MY, Li J, Li YY, Hsieh MY, Yang CJ, Chen YJ, Li Y, Chen HC, Cheng WE, Hsieh CY, **Cheng CW**, Leu TZ. The iNOS/Src/FAK axis is critical in Toll-like receptor-mediated cell motility in macrophages. *Biochim Biophys Acta-Mol Cell Res* 2011; 1813:136-147. (IF=5.538; Ranking=45/290, Biochemistry & Molecular Biology)
30. Wu SL, Wang WF, Shyu HY, Ho YJ, Shieh JC, Fu YP, Wu ST, **Cheng CW***. Association analysis of GRIN1 and GRIN2B polymorphisms and Parkinson's disease in a hospital-based case-control study. *Neurosci Lett* 2010; 478:61-65. (IF=2.105; Ranking=170/244, Neurosciences)
31. Ding SL, Yu JC, Chen ST, Hsu GC, Hsu HM, Ho JY, Lin YH, Chang CC, Fann CS, **Cheng CW**, Wu PE, Shen CY. Diverse associations between ESR1 polymorphism and breast cancer development and progression. *Clin Cancer Res* 2010; 16:3473-3484. (IF=7.338; Ranking=16/185, Oncology)
32. Shyu HY, Fong CS, Fu YP, Shieh JC, Yin JH, Chang CY, Wang HW, **Cheng CW***. Genotype polymorphisms of GGCX, NQO1, and VKORC1 genes associated with risk susceptibility in patients with large-artery atherosclerotic stroke. *Clin Chim Acta* 2010; 411:840-845. (IF=2.535; Ranking=6/32, Medical Laboratory Technology)
33. Hsu MS, Yu JC, Wang HW, Chen ST, Hsiung CN, Ding SL, Wu PE, Shen CY, **Cheng CW***. Synergistic effects of polymorphisms in DNA repair genes and endogenous estrogen exposure on female breast cancer risk. *Ann Surg Oncol* 2010; 17:760-771. (IF=4.182; Ranking=8/188, Surgery)
34. **Cheng CW***, Yu JC, Wang HW, Huang CS, Shieh JC, Fu YP, Chang CW, Wu PE and Shen CY. The clinical implications of MMP-11 and CK-20 expression in human breast cancer. *Clin Chim Acta* 2010; 411:234-241. (IF=2.535; Ranking=6/32, Medical Laboratory Technology)
35. Yu JC, Ding SL, Chang CH, Kuo SH, Chen ST, Hsu GC, Hsu HM, Hou MF, Jung LY, **Cheng CW**, Wu PE, Shen CY. Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes. *Carcinogenesis* 2009; 30:1562-1570. (IF=4.930; Ranking=27/143, Oncology)
36. **Cheng CW***, Yu JC, Huang CS, Shieh JC, Fu YP, Wang HW, Wu PE, Shen CY. Polymorphism of cytosolic serine hydroxymethyltransferase, estrogen and breast cancer risk among Chinese women in Taiwan. *Breast Cancer Res Treat* 2008; 111:145-155. (IF=5.684; Ranking=17/143, Oncology)
37. Lee YT, Wang WF, **Cheng CW**, Wu SL, Pawlak CR, Ho YJ. Effects of escapable and inescapable stressors on behavior and interleukin-2 in the brain. *Neuroreport* 2008;

19:1243-1247. (IF=1.904; Ranking=153/221, Neurosciences)

38. Huang CS, Shen CY, WuPY, Wang HW, **Cheng CW***. Increased expression of *SRp40* affecting *CD44* splicing is associated with clinical outcome of lymph node metastasis in human breast cancer. *Clin Chim Acta* 2007; 384:69-74. (IF=2.960; Ranking=5/27, Medical Laboratory Technology)
39. Fong CS, Wu RM, Shieh JC, Chao YT, Fu YP, Kuao CL, **Cheng CW***. Pesticide exposure on southwestern Taiwanese with MnSOD and NQO1 polymorphisms is associated with increased risk of Parkinson's disease. *Clin Chim Acta* 2007; 378:136-141. (IF=2.960; Ranking=5/27, Medical Laboratory Technology)
40. Chern HD, Ueng TH, Fu YP, **Cheng CW***. CYP2C9 polymorphism and warfarin sensitivity in Taiwanese Chinese. *Clin Chim Acta* 2006; 367:108-13. (IF=2.960; Ranking=5/27, Medical Laboratory Technology)
41. Chang YH, Wang L, Lee MS, **Cheng CW**, Wu CY, Shiau MY. Direct genotypic characterization of *Helicobacter pylori cagA* and *vacA* from biopsy specimens of patients with gastroduodenal diseases in Taiwan. *Mount Sinai J Med* 2006;73:622-26. (IF=1.063; Ranking=56/103, Medicine, General & Internal)
42. Fong CS, **Cheng CW**, Wu RM. Pesticides exposure and genetic polymorphism of paraoxonase in the susceptibility of Parkinson's disease. *Acta Neurol Taiwan* 2005;14:55-60.
43. Cheng TC, Chen ST, Huang CS, Fu YP, Yu JC, **Cheng CW**, Wu PE, Shen CY. Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: A multigenic study on cancer susceptibility. *Int J Cancer* 2005; 113:345-53. (IF=4.700; Ranking=22/123, Oncology)
44. Huang CS, Chen JJ, Yang SY, **Cheng CW**, Chern HD, Chang KJ, Wu PE, Shen CY. Breast cancer risk associated with genotypic polymorphism of oxidative DNA damage repair genes - A multigenic study of base excision repair and transcription-coupled repair in cancer susceptibility. *J Genet Mol Biol* 2004; 5:116-36.
45. Wu RM, **Cheng CW**, Chen KH, Shan DE, Kuo JW, Ho YF, Chern HD. Genetic polymorphism of the CYP2E1 gene and susceptibility to Parkinson's disease in Taiwanese. *J Neural Transm* 2002; 109:1403-1414. (NSC 89-2314-B-002-143 and NSC 89-2314-002-566)(IF=2.289; Ranking=34/138, Clinical Neurology)
46. **Cheng CW**, Wu PE, Yu JC, Huang CS, Yue CT, Wu CW, Shen CY. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. *Oncogene* 2001; 20:3814-23. (IF=6.737; Ranking=7/107, Oncology)
47. Wu RM, **Cheng CW**, Chen KH, Lu SL, Shan DE, Ho YF, Chern HD. The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese. *Neurol* 2001; 56:375-82. (NSC 89-2314-B-002-143) (IF=2.289; Ranking=34/138, Clinical Neurology)
48. **Cheng CW**, Chueh SC, Chern HD. Diagnosis of bladder cancer using telomerase activity

in voided urine. *J Formos Med Assoc* 2000; 99:920-25. (IF=5.212; Ranking=6/136, Clinical Neurology)

49. **Cheng CW**, Lin JS, Liu YT, Yang SS. Cloning and expression of α -amylase gene and oxytetracycline production in *Streptomyces rimosus*. *World J Microbiol Biotechnol* 2000; 16:225-30. (IF=0.538; Ranking=99/133, Biotech & Appl Microbiol)
50. Huang CS, Chern HD, Chang KJ, **Cheng CW**, Hsu SM, Shen CY. Breast cancer risk associated with genotype polymorphism of estrogen metabolizing genes, CYP17, CYP1A1 and COMT-a multigenic study on cancer susceptibility. *Cancer Res* 1999; 59:4870-5. (IF=8.614; Ranking=4/105, Oncology)

(三) 計劃總表

學年度	姓名	政府機關	非政府機關
108	鄭鈞文	1	0
107	鄭鈞文	1	0
106	鄭鈞文	0	0
105	鄭鈞文	1	0
104	鄭鈞文	1	0
103	鄭鈞文	1	0
102	鄭鈞文	1	0
101	鄭鈞文	0	1
100	鄭鈞文	1	0
99	鄭鈞文	1	0
98	鄭鈞文	1	0
97	鄭鈞文	1	1
96	鄭鈞文	1	0
總計		11	2

研究室經費來源：科技部、學界，計畫列表，說明如下

(1)、國科會、科技部歷年研究計畫補助

1. 以基因體關聯研究(GWAS)定位核苷酸多形性調控 microRNA 轉錄表現於乳癌預後之角色探討 (科技部 108-2314-B-040-026-; 2019/08/01~2020/07/31)
2. 微型核糖核酸結合 CCND2 和 Cathepsin D 抑制乳癌進程發展之機制探討及臨床預後意義(科技部 107-2314-B-040-022-; 2018/08/01~2019/07/31)
3. 以 Argonaute2 為標的探討熊果酸影響乳癌腫瘤幹細胞生成之抑癌功能 (科技部 107-2320-B-040-012-; 2018/08/01~2019/07/31)
4. 探討 Argonaute2 訊息傳遞於調控乳癌腫瘤幹細胞生成及抗藥性之轉譯醫學研究(科技部 105-2314-B-040-004-; 2016/08/01~2017/07/31)

5. 微型核糖核酸影響腫瘤微環境和乳癌進程之外顯基因體學研究--侵襲轉移機制探討及其預後標記分析 (科技部 102-2628-B-040-002-MY3; 2013/08/01~2016/07/31)
6. 微型核糖核酸矩陣分析探討女性乳癌癌化進程之遺傳標 (國科會 98-2314-B-040-009-MY3; 2009/08/01~2012/07/31)
7. microRNAs 標的遺傳序列之甲基化形式和功能表現在婦女乳癌進程之角色探討(國科會 97-2314-B-040-013-; 2008/08/01~2009/07/31)
8. 動情激素受體在乳癌生成進程之角色探討 (國科會 95-2314-B-040-030-MY2; 2006/08/01~2008/07/31)
9. FANCD2 之活化與 BRCT 的交互作用及其 FANCD2 基因多形性與乳癌發生關聯之分子遺傳學研究 (國科會 93-2320-B-040-022; 2004/08/01~2005/07/31)
10. 乳癌分子流行病學研究--BRCA1 與 FANCD2 基因多形性對 DNA 雙股錯結修復作用於乳癌發生所扮演之角色 (國科會 92-2320-B-040-058-; 2003/08/01~2004/07/31)
11. 乳癌淋巴轉移相關基因表現之複合性研究 (國科會 91-2320-B-264-002-; 2002/08/01~2003/07/31)
12. 胸腺嘧啶之甲基移轉代謝機制與乳癌形成的關聯性研究 (國科會 90-2320-B-264-003-; 2001/12/01~2002/07/31)

(2)、其它機構申請研究計畫補助

1. 微型核糖核酸影響上皮細胞間質轉化和乳癌癌化進程與其臨床預後標記評估之研究 (中山醫大特色領域計畫 CSMU-INT-101-03; 2012/08/01 ~ 2013/07/31)
2. DNA 修復基因、動情激素與乳癌致癌易感受性關聯之探討 (中山醫大院際合作計畫 CSMU-LMC-097-003; 2008/08/01 ~ 2009/07/31)
3. 分析山藥之薯蕷皂素內含量並以細胞趨化性為研究標的建立評估山藥薯蕷皂素抑制乳癌細胞增生及惡化之功能 (衛生署 DOH95-TD-F-113-018; 2006/01/01~2006/12/31)

(四) 連絡方式:

鄭鈞文教授：研究大樓五樓 509 室

電話: 04-24730022 分機 11677

E-mail : cwcheng@csmu.edu.tw

(三) 實驗室成員：

專任研究助理：1 人

碩士班研究生：1 人

大學部專題生：4 人


研究室精神：

積極進取，主動學習



年終尾牙聚餐

(四) 重要研究成果



109 年度為(2020.1-2020.12)
108 年度為(2019.1-2019.12)
107 年度為(2018.1-2018.12)
106 年度為(2017.1-2017.12)
105 年度為(2016.1-2016.12)
104 年度為(2015.1-2015.12)
103 年度為(2014.1-2014.12)
102 年度為(2014.1-2014.12)
101 年度為(2012.1-2012.12)
100 年度為(2011.1-2011.12)
99 年度為(2010.1-2010.12)
98 年度為(2009.1-2009.12)
97 年度為(2008.1-2008.12)
96 年度為(2007.1-2007.12)